<DOC>
	<DOCNO>NCT00922896</DOCNO>
	<brief_summary>The purpose study determine response rate gemcitabine , cisplatin erlotinib metastatic pancreatic cancer .</brief_summary>
	<brief_title>Trial Erlotinib , Gemcitabine Cisplatin Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age old 18 Younger 75 ECOG performance status 0 1 Histologically confirm adenocarcinoma pancreas Metastatic pancreatic cancer No prior chemotherapy metastatic pancreatic cancer A patient least one measurable primary lesion diameter confirm 10mm Spiral CT multidetector CT ( MD CT ) A patient measurable disease A patient receive previous palliative chemotherapy pancreatic cancer A patient locally advanced pancreatic cancer A patient receive adjuvant chemotherapy pancreatic cancer within 1 year A patient previous active passive immunotherapy A pregnant lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Erlotinib</keyword>
</DOC>